Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Nov 2026

Expert consensus on the diagnosis and treatment of EGFR gene mutation non-small cell lung cancer

Abstract Background: Epidermal growth factor receptor (EGFR) mutations are the most clinically actionable oncogenic drivers in Asian patients with non-small-cell lung cancer (NSCLC). The therapeutic landscape has rapidly evolved from single-agent EGFR tyrosine kinase inhibitors (TKIs) to risk-adapted first-line intensi...

R. Meng, Chun-Wei Xu, Wen-Xian Wang et al. · 0 citations
Review Open access Oct 2026

Efficacy and safety of risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed/refractory advanced osteosarcoma: Primary results from the ARTEMIS-011 phase 3 trial.

BACKGROUND Patients with relapsed/refractory (R/R) osteosarcoma have a poor prognosis and high unmet needs for effective therapies. Herein, we report primary results from ARTEMIS-011, the multicenter, open-label, randomized phase 3 trial of risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, in Ch...

L. Xie, W. Yao, Y. Hua et al. · 2 citations
Aug 2026

Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma.

PURPOSE Patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) have limited therapeutic options after failing platinum and anti-PD-1/PD-L1 therapy. We investigated the efficacy and safety of an epidermal growth factor receptor (EGFR)-directed antibody-drug conjugate (ADC) becotatug vedotin (BV) combin...

Dan-Yun Ruan, Feng-hua Wang, Yu-Juan Zhou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.